Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold reco
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. Two equities resea… [+3442 chars]
 Target Price at $3.50&url=https://worldnews.easybranches.com//lifestyle/natural-medicines/14943216&media=https://worldnews.easybranches.com/images/2024/12/750x495/14943216.jpg){kind=link}